Eli Lilly said on Thursday its experimental obesity drug helped patients lose as much as 20.1% of their weight in a mid-stage ...
Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging ...
Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of ...
Eli Lilly (LLY) stock is in focus as the company's amylin receptor agonist eloralintide helped patients lose up to 20% body ...
A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.
Stocktwits on MSN
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years?
Eli Lilly led a Stocktwits poll, with 32% support, ahead of Novo Nordisk, Hims & Hers Health and Viking Therapeutics at 16%. ...
An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...
Eli Lilly and Co expects the U.S. Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as ...
The Hollywood star sat down with Newsweek to discuss his next big project: upping enrollment in clinical trials.
The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback